Back to Stocks

INAB

IN8BIO, INC.
7 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

IN8BIO is demonstrating a masterclass in clinical-stage capital efficiency.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of 'disciplined burn,' the financial reality revealed in the 10-Q is precarious. The company explicitly admits there is substantial doubt about its ability to continue as a going concern, with auditors noting a runway of less than 18 months.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every INAB filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark contrast between technical scientific potential and fiscal fragility. While the clinical data for the DeltEx platform remains encouraging, the company is operating on a razor-thin margin of error. The transition from a cash-burning developer to a partnership-ready asset depends entirely on the company's ability to secure non-dilutive capital or strategic collaborations before its current reserves are exhausted. Investors are essentially betting on a race between the clinical clock and the financial clock. If the company can successfully navigate the regulatory and funding hurdles to reach the late 2026 data readouts, the upside is significant. However, the 'substantial doubt' language in the filing serves as a critical warning that the path to those milestones is fraught with the risk of insolvency or extreme dilution.

Selected Quarter

Core Takeaway

IN8BIO has a promising pipeline but is facing a critical cash shortage, leading to a 'going concern' warning from auditors.

Investor Lens

The trade-off is between the high-reward potential of the DeltEx platform and the high probability of significant equity dilution.

Watch Next

Phase 1 expansion data for INB-100 and any new strategic collaboration announcements in 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.40Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%
bearishMay 7

Company reports substantial doubt about ability to continue as a going concern due to cash burn.

margin compression
70%
bullishMay 7

Quarterly operating expenses decreased by approximately 7% year-over-year.

margin expansion
40%
bearishMay 7

High risk of dilution from outstanding warrants and limited ATM capacity under baby-shelf rules.

dilution risk
90%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a stark contrast between technical scientific potential and fiscal fragility. While the clinical data for the DeltEx platform remains encouraging, the company is operating on a razor-thin margin of error. The transition from a cash-burning developer to a partnership-ready asset depends entirely on the company's ability to secure non-dilutive capital or strategic collaborations before its current reserves are exhausted. Investors are essentially betting on a race between the clinical clock and the financial clock. If the company can successfully navigate the regulatory and funding hurdles to reach the late 2026 data readouts, the upside is significant. However, the 'substantial doubt' language in the filing serves as a critical warning that the path to those milestones is fraught with the risk of insolvency or extreme dilution.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.